Immunome Inc Forecast, price target & analysts
Immunome Inc Target price 2025 - Analyst rating & recommendation
Immunome Inc Classifications & Recommendation:
Immunome Inc Price Target
| Target Price | $27.14 |
| Price | $6.71 |
| Potential |
304.51%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Immunome Inc 2026 .
The average Immunome Inc target price is $27.14.
This is
304.51%
register free of charge
$38.00
466.32%
register free of charge
$20.00
198.06%
register free of charge
|
|
| A rating was issued by 8 analysts: 8 Analysts recommend Immunome Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2026 of
304.51%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.04 | 1.30 |
| 35.52% | 85.57% | |
| EBITDA Margin | -1,674.23% | -20,697.79% |
| 115.74% | 1,136.26% | |
| Net Margin | -3,565.27% | -13,860.64% |
| 44.13% | 288.77% |
7 Analysts have issued a sales forecast Immunome Inc 2025 . The average Immunome Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Immunome Inc 2025 . The average Immunome Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Immunome Inc Analysts have issued a net profit forecast 2025. The average Immunome Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.00 | -2.81 |
| 7.06% | 43.80% | |
| P/E | negative | |
| EV/Sales | 284.38 |
4 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is
This results in the following potential growth metrics and future valuations:
Current Immunome Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Lake Street |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Lake Street:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 14 2024 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
